|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of products sold | |||||
| Gross margin | |||||
| Operating expenses: | |||||
| Distribution, selling, general, and administrative expenses | |||||
| Restructuring and employee severance | |||||
| Amortization and other acquisition-related costs | |||||
| Acquisition-related cash and share-based compensation costs | |||||
| Impairments and (gain)/loss on disposal of assets, net | |||||
| Litigation (recoveries)/charges, net | |||||
| Operating earnings | |||||
| Other (income)/expense, net | |||||
| Interest expense, net | |||||
| Loss on early extinguishment of debt | |||||
| (Gain)/Loss on sale of equity interest in naviHealth | |||||
| Equity Method Investment, Other-than-Temporary Impairment | |||||
| Earnings before income taxes | |||||
| Income Tax Expense (Benefit) | |||||
| Net earnings | |||||
| Less: Net (earnings)/loss attributable to noncontrolling interests | |||||
| Net earnings attributable to Cardinal Health, Inc. | |||||
| Earnings per common share attributable to Cardinal Health, Inc. | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average number of common shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
